Clinical Edge Journal Scan

Early emollient bathing is tied to the development of atopic dermatitis by 2 years of age


 

Key clinical point: Emollient bathing at 2 months is significantly associated with the development of atopic dermatitis (AD) by 2 years of age.

Major finding: The odds of developing AD were significantly higher among infants who had emollient baths and frequent (> 1 time weekly) emollient application at 2 months of age compared with infants who had neither at 6 months (adjusted odds ratio [aOR] 1.74; P =  .038), 12 months (aOR 2.59; P < .001), and 24 months (aOR 1.87; P = .009) of age.

Study details: Findings are from a secondary analysis of the observational Cork BASELINE Birth Cohort Study and included 1505 healthy firstborn term infants who did or did not receive emollient baths and did or did not have emollients applied frequently at 2 months of age.

Disclosures: This study was supported by the Science Foundation Ireland and Johnson & Johnson Santé Beauté France. J O’B Hourihane declared receiving research funding, speaker fees, and consulting fees from various sources.

Source: O'Connor C et al. Early emollient bathing is associated with subsequent atopic dermatitis in an unselected birth cohort study. Pediatr Allergy Immunol. 2023;34(7):e13998 (Jul 18). doi: 10.1111/pai.13998

Recommended Reading

Probiotic intake by breastfeeding mothers halves the incidence of atopic dermatitis in children
MDedge Dermatology
Sibship composition and size alter the risk for atopic dermatitis
MDedge Dermatology
Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
MDedge Dermatology
Free teledermatology clinic helps underserved patients initiate AD care
MDedge Dermatology
Economic Burden and Quality of Life of Patients With Moderate to Severe Atopic Dermatitis in a Tertiary Care Hospital in Helsinki, Finland: A Survey-Based Study
MDedge Dermatology
Nemolizumab shows promise in pediatric atopic dermatitis with inadequately controlled pruritus
MDedge Dermatology
Amlitelimab is effective and well-tolerated in atopic dermatitis inadequately controlled by topical therapies
MDedge Dermatology
Continuous upadacitinib treatment required to maintain skin clearance in atopic dermatitis
MDedge Dermatology
Abrocitinib is safe and effective against difficult-to-treat atopic dermatitis in daily practice
MDedge Dermatology
Cannabis use is more prevalent in patients with atopic dermatitis
MDedge Dermatology